Skip to main content
. 2015 Jul-Aug;26(4):207–211. doi: 10.1155/2015/136568

TABLE 1.

Baseline and time-dependent patient characteristics according to ethnicity (n=411)

Variables Total sample (n=411) First Nations or Métis (n=257, 70.8%) Others* (n=106, 29.2%)
Follow-up time, months, median (IQR) 27.6 (31.9) 27.6 (29.9) 32.6 (37.7)
Variable at baseline
Age at enrollment, years, mean ± SD 35.7±10.3 33.7±9.1 41±11.5
Exposure category
  MSM 21 (6.5) 1(0.5) 20 (22.0)
  MSM/IDU 12 (3.7) 5 (2.3) 6 (6.6)
  IDU 244 (75.5) 193 (89.8) 36 (39.5)
  Heterosexual contact 46 (14.2) 16 (7.4) 29 (31.9)
Site
  PLP 188 (45.7) 100 (38.9) 80 (75.5)
  WSCC 122 (29.7) 84 (32.7) 7 (6.6)
  Both 101 (24.6) 73 (28.4) 19 (17.9)
CD4+ count, cells/µL
  n, mean ± SD 300, 379±233 181, 369±218 87, 376±236
  Missing, n 111 76 19
CD4+ count, cells/µL
  <200 68 (22.7) 39 (21.6) 21 (24.1)
  200–350 88 (29.3) 60 (33.1) 22 (25.3)
  >350 144 (48.0) 82 (45.3) 44 (50.6)
Log10 of viral load, copies/mL
  n, mean ± SD 276, 4.3±1.0 167, 4.2±1.0 85, 4.4±1.0
  Missing, n 135 90 21
HCV antibody positive 312 (80.2) 227 (92.6) 47 (46.5)
  Missing, n 22 12 5
History of IDU 300 (73.3) 222 (87.1) 43 (40.6)
  Missing, n 2 2
STI 134 (32.6) 86 (33.5) 38 (35.8)
Time-dependent variables
Incarcerated during follow-up 118 (28.7) 89 (34.6) 22 (20.7)
Ever use of social assistance 146 (35.5) 110 (42.8) 25 (23.6)
Ever use of ART 257 (62.5) 167 (65.0) 70 (66.0)
ART naïve 154 (37.5) 90 (35.0) 36 (34.0)
Case management 54 (13.1) 45 (17.5) 4 (3.8)
Clinical AIDS 30 (7.3) 18 (7.0) 12 (11.3)
All-cause mortality 29 (7.1) 20 (7.8) 8 (7.5)

Data presented as n (%) unless otherwise indicated.

*

48 were missing;

88 were missing. ART Antiretroviral therapy; HCV Hepatitis C virus, IDU Injection drug use; IQR Interquartile range; MSM Men who have sex with men; PLP Positive Living Program; STI Sexually transmitted infection; WSCC Westside Community Clinic